Tirzepatide, branded as Mounjaro for diabetes and ZepBound for weight loss, typically starts at 2.5 mg per week and can increase to 15 mg
Adderall (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets) prescribing information, Food and Drug Administration (2024) Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules prescribing information, Food and Drug Administration (2023) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Ozempic (semaglutide) injection prescribing information, Food and Drug Administration (2023) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
How is semaglutide prescribed through telehealth
The SELECT trial is a major breakthrough, says Yale Medicine cardiologist Harlan Krumholz, MD, SM, explaining that while semaglutide [given as Ozempic] was already known to lower the risk of heart disease in people with diabetes, the SELECT trial was the first to show that Wegovy, which contains a higher dose of semaglutide, also lowers that risk even in people who dont have diabetes
